Sinovac Biotech (SVA) Stock Statistics & Valuation Metrics

Sinovac Biotech has a market cap or net worth of $460.27M. The enterprise value is ―.

Sinovac Biotech has 71,860,700 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sinovac Biotech’s return on equity (ROE) is -0.01 and return on invested capital (ROIC) is -7.33%.

The current PE Ratio of Sinovac Biotech is -6.45. Sinovac Biotech’s PEG ratio is ―.

In the last 12 months, Sinovac Biotech had revenue of 448.27M and earned -99.92M in profits. Earnings per share was -1.06.

In the last 12 months, operating cash flow was 106.02M and capital expenditures -145.69M, giving a free cash flow of -39.67M billion.

Sinovac Biotech pays an annual dividend of $55, resulting in a dividend yield of ―

Sinovac Biotech upcoming earnings date is Aug 14, 2025, TBA Not Confirmed.

Sinovac Biotech as a current ratio of 10.31, with Debt / Equity ratio of 3.43%

In the past 12 months, Sinovac Biotech has paid 105.32M in taxes.

Sinovac Biotech EV to EBITDA ratio is 54.19, with an EV/FCF ratio of 7.84.

Sinovac Biotech has $11.22B in cash and marketable securities with $298.98M in debt, giving a net cash position of -$10.92B billion.

Gross margin is 59.51%, with operating margin of -121.96%, and net profit margin of -22.29%.

The average price target for Sinovac Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―